Chattanooga Medical Research takes the health and safety of all staff, patients, seriously. With the vast number of growing cases of the Coronavirus (COVID-19), we want to take the opportunity to assure you that we are prepared in this ever-changing situation. We are following the advice of public health professionals and medical experts, as well as adhering to the current guidelines issued by the Center for Disease Control (CDC) and the World Health Organization (WHO). Our team at CMR is making every effort to continue to execute clinical trials while protecting the health and safety of our patients and entire staff.

If you are interested in participating in any of our trials, please fill out the on-line study inquiry form and a member of our team will contact you promptly.

CHATTANOOGA MEDICAL RESEARCH, LLC (CMR)

CMR is a privately owned multi-specialty clinical research facility. Our research team consist of a group of Board Certified OB-GYN and Internal Medicine Investigators, Physician Assistant, ACRP Certified Clinical Research Coordinators, Quality Assurance Specialist (ACRP Certified) and Data Entry Specialist.

Our facility conducts Phase II-IV clinical trials. We are dedicated to achieving excellence in the quality of science, providing the best possible research experience for sick and healthy subjects alike and enforcing the highest standards of biomedical ethics for the conduct of research.

Our center is a well known research center in the local community, surrounding areas and the pharmaceutical industry, due to its reputation for having extensively trained employees who are highly dedicated and devoted in providing the highest standards of patient care at all times. Our entire clinical team is committed to producing highly effective and efficient data in an effort to facilitate FDA approval and bring new treatment options to the market.

In addition, due to the underrepresentation of minorities in clinical trials, CMR has taken the approach to increase enrollment of the diverse populations in our community. More diverse representation in trials is needed to gain insight that will make medicines most effective for all that may have a need for them.